PRNewswire

WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years On Track to Submit sNDA for Pitolisant in Idiopathic Hypersomnia (IH) in Q4 2024 Based on Updated Strong and Sustained Efficacy Data from Long-Term Extension Study

Debt-Free Milestone: Valour Inc. has eliminated its outstanding debt with a final C$5.5 million (US$4 million) payment, completed on October 16, 2024, strengthening its financial position. Strategic Growth and Expansion: This debt elimination allows Valour to focus resources on growth, innovation, a

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: